<DOC>
	<DOCNO>NCT00433719</DOCNO>
	<brief_summary>The optimal time initiate antiretroviral therapy ( ART ) HIV-associated tuberculous meningitis ( TBM ) unknown . There concern immediate ART may worsen rather improve outcome , drug interactiond toxicity development intracerebral immune reconstitution inflammatory syndrome ( IRIS ) . Conversely , delay ART may result increase HIV-related death . To answer question , conduct randomise , double-blind placebo-controlled trial compare immediate deferred ART HIV-infected patient present TBM , assess effect survival .</brief_summary>
	<brief_title>Immediate Versus Deferred Antiretroviral Therapy HIV-Associated Tuberculous Meningitis</brief_title>
	<detailed_description>Title : Study immediate versus defer antiretroviral therapy HIV-associated tuberculous meningitis Study design : A randomized , double blind , placebo-controlled trial 2 parallel arm Sample size : 247 Inclusion criterion : Age 15 year old ; HIV antibody positive ; clinical diagnosis TBM . Exclusion criterion : positive CSF Gram India ink stain , know suspected pregnancy ; antituberculous treatment 8 30 day immediately prior recruitment ; previous antiretroviral therapy ; laboratory contraindication antiretroviral antituberculous therapy ; lack consent . Consent : Written inform consent sought patient . Verbal consent consider acceptable write consent impossible . In unconscious patient , consent 2 independent physician consider acceptable . Randomization : Patients stratify accord TBM disease severity presentation ( modify MRC grade I III ) . Within stratum , patient randomize 1 2 treatment arm : immediate defer ( 2 month ) ART . Antituberculous treatment : Initial therapy isonazid , rifampicin , pyrazinamide ethambutol 3 month . After 3 month , patient continue rifampicin isoniazid 6 month . Corticosteroid treatment : Dexamethasone 0.3 - 0.4mg/kg administer taper 6 - 8 week , accord TBM grade . Antiretrovira l treatment : Antiretrovirals ( zidovudine , lamivudine efavirenz ) identical placebo tablet commence study entry continue 2 month . Thereafter , patient receive antiretrovirals . Clinical monitoring : Patients assess weekly inpatient 3 month . Hospital outpatient review occur monthly 9 month . A final follow-up visit take place 12 month . Laboratory monitoring : Routine laboratory test monitor weekly inpatient monthly outpatient . Blood sample CD4 T-lymphocyte count plasma HIV-1 RNA level monitor 3-monthly . CSF sample take 0 , 1 , 2 , 3 , 6 9 month . Radiology : Patients chest radiograph perform admission . A CT MRI brain scan may also perform clinically indicate . Adverse event : All grade 3 4 adverse event report immediately Data Safety Monitoring Committee . Outcome measure : The primary endpoint mortality 9 month . The secondary endpoint : mortality 12 month ; fever clearance time ; coma clearance time ; neurological relapse ; progression new recurrent AIDS defining illness ; grade 3 4 adverse event ; CD4 count response ; plasma HIV-1 RNA response ; neurological disability . Data analysis : Analysis base intention treat .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Meningeal</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<criteria>age 15 year old HIV antibody positive clinical diagnosis TB meningitis positive CSF Gram India ink stain know suspected pregnancy antituberculous treatment 8 30 day immediately prior recruitment previous antiretroviral therapy laboratory contraindication antiretroviral antituberculous therapy lack consent .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Human immunodeficiency virus</keyword>
	<keyword>Tuberculous meningitis</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>